The CASPIAN trial confirmed significantly longer overall survival following first-line treatment with the PD-L1 antagonist durvalumab in addition to platinum-based chemotherapy in patients with extensive stage SCLC [56]. The gene discussed is CD274; the disease is small cell lung carcinoma.